Valuation: Keros Therapeutics, Inc.

Market Cap 223M 195M 179M 167M 317M 21.22B 321M 2.15B 836M 10.43B 837M 819M 35.94B P/E 2026 *
-1.88x
P/E 2027 * -2.06x
Enterprise Value 223M 195M 179M 167M 317M 21.22B 321M 2.15B 836M 10.43B 837M 819M 35.94B EV / Sales 2026 *
52.4x
EV / Sales 2027 * 11.8x
Free-Float
46.57%
Yield 2026 *
-
Yield 2027 * -
1 day+3.49%
1 week+2.46%
Current month+5.23%
1 month+7.24%
3 months-6.17%
6 months-39.27%
Current year-44.70%
1 week 10.57
Extreme 10.57
11.42
1 month 9.69
Extreme 9.69
11.47
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 2015-11-30
Director of Finance/CFO 56 2020-01-31
Chief Tech/Sci/R&D Officer 53 2019-05-31
Director TitleAgeSince
Chairman 70 2024-06-30
Director/Board Member 63 2016-03-31
Director/Board Member 50 2020-02-29
Date Insider Type Main position Quantity % Market Cap.
06-14Buy

Chairman

1,000 0.0051%
06-10Sell

Director

-550 0.0028%
06-03Sell

Director

-2,625 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+3.49%+2.46%-16.28%-71.76% 223M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.93%+8.53%+47.54%+123.61% 24.57B
Weighted average by Cap. +2.46%+6.48%+58.99%+137.51%

Financials

2026 *2027 *
Net sales 4.25M 3.72M 3.42M 3.18M 6.04M 405M 6.13M 41.01M 15.94M 199M 15.96M 15.62M 686M 18.91M 16.53M 15.19M 14.16M 26.86M 1.8B 27.27M 182M 70.9M 885M 70.98M 69.46M 3.05B
Net income -120M -105M -96.77M -90.2M -171M -11.47B -174M -1.16B -452M -5.64B -452M -442M -19.43B -132M -115M -106M -98.83M -187M -12.57B -190M -1.27B -495M -6.18B -495M -485M -21.29B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
87
Date Price Change Volume
26-07-02 US$11.26 +3.49% 403,611
26-07-01 US$10.88 +1.68% 210,616
26-06-30 US$10.70 -2.10% 289,055
26-06-29 US$10.93 -0.55% 353,292
26-06-26 US$10.99 +5.57% 1,433,696
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.26USD
Average target price
21.83USD
Spread / Average Target
+93.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock